Iovance Biotherapeutics, Inc. has updated its full-year 2026 total revenue guidance to a range of $410 million to $420 million. This represents an increase of $55 million at the midpoint compared to the previous guidance range of $350 million to $370 million.
The company attributes this upward revision to strong U.S. demand for its commercial products, Amtagvi (lifileucel) and Proleukin. According to the filing, the new guidance implies nearly 60% annual growth in total revenue.
Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer of Iovance, stated that record second-quarter performance and sustained demand for the company's therapies led to the adjustment. The company noted that increasing patient demand and its current manufacturing schedule provide visibility into third and fourth quarter revenues.
As of the press release, Iovance reported record second quarter 2026 total product revenue of $99.3 million. The company has grown its authorized treatment center (ATC) network to approximately 100 centers and remains on track for expansion to at least 110 ATCs by the end of 2026.
Iovance expects to report third quarter 2026 financial results in early November 2026.
